Abcellera Biologics INC. 8-K Filing

Filing Documents

• abcl-20251218.htm (8-K) — 25KB
• a2025-12x18brukerlitigat.htm (EX-99.1) — 4KB
• a2025-12x18brukerlitigat001.jpg (GRAPHIC) — 261KB
• 0001703057-25-000034.txt ( ) — 499KB
• abcl-20251218.xsd (EX-101.SCH) — 2KB
• abcl-20251218_lab.xml (EX-101.LAB) — 20KB
• abcl-20251218_pre.xml (EX-101.PRE) — 12KB
• abcl-20251218_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On December 18, 2025, AbCellera Biologics Inc. issued a press release announcing it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between the two companies globally. A copy of the press release is furnished herewith as Exhibit 99.1. The information in Item 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued by AbCellera Biologics Inc. on December 18 , 2025. 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 18, 2025 ABCELLERA BIOLOGICS INC. By: /s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR